• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

    13.44 -0.17 (-1.25%)
    Streaming Delayed Price Updated: 11:42 AM EDT, Apr 29, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Viridian Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Prepares for Transformational 2026
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Proposed Underwritten Public Offering
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
    From Viridian Therapeutics, Inc.
    Via Business Wire
    News headline image
    Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
    From Viridian Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.